Kezar Life Sciences, INC

Kezar Life Sciences, Inc. has been acquired by Aurinia Pharma U.S., Inc. following the successful completion of a tender offer and subsequent merger.

Kezar Life Sciences announced the termination of a significant lease agreement and the departure of its CEO, CFO, and COO, coinciding with details of its pending acquisition by Aurinia Pharmaceuticals.

Kezar Life Sciences agreed to a tender offer from Aurinia Pharma U.S. at $6.955 per share in cash plus a non‑tradable CVR tied to zetomipzomib, collaboration proceeds and excess net cash, with closing targeted for Q2 2026.

Kezar Life Sciences divests its Sec61-based discovery and development program, including KZR-261, to Enodia Therapeutics for an upfront payment and up to $127 million in milestones plus royalties.

Kezar Life Sciences announced third-quarter 2025 financial results, revealing a significant workforce reduction and a strategic review following an FDA setback for its lead drug candidate, zetomipzomib.

Kezar Life Sciences, Inc. announced a significant restructuring plan on November 6, 2025, reducing its workforce by approximately 70% and anticipating $6.0 million in related costs.

Kezar Life Sciences filed its Q1 2026 10-Q, detailing financial performance and ongoing merger activities with Aurinia Pharma.

Kezar Life Sciences is exploring strategic alternatives to maximize stockholder value, following significant clinical program terminations and a 70% workforce reduction.

Kezar Life Sciences reported a reduced net loss and lower operating expenses for the first half of 2025, driven by a strategic shift to focus on autoimmune hepatitis after terminating a key lupus nephritis trial.

Kezar Life Sciences reports a net loss of $16.6 million for Q1 2025, shifting focus to autoimmune hepatitis (AIH) program.

Kezar Life Sciences announced its third quarter 2024 results, including a net loss of $20.3 million, and the termination of its PALIZADE trial for lupus nephritis.

Kezar Life Sciences reports a net loss of $43.2 million for the first six months of 2024, while focusing on clinical development of zetomipzomib.

Kezar Life Sciences details its 2024 financial performance and strategic shift towards developing zetomipzomib for autoimmune hepatitis.

Kezar Life Sciences' 10-K filing outlines the company's capital structure, including authorized shares of common and preferred stock, and details anti-takeover provisions.

Courtney reports changes in beneficial ownership of Kezar Life Sciences stock options following a merger.

Mark C. Schiller's Form 4 details the cancellation and conversion of his stock options following Kezar Life Sciences' merger with Aurinia Pharma.

Micki Klearman, a Director at Kezar Life Sciences, Inc., reported transactions related to stock options on May 11, 2026, following a merger.

Christopher J. Kirk, CEO of Kezar Life Sciences, reported changes in beneficial ownership following the company's merger with Aurinia Pharma U.S., Inc.

Kezar Life Sciences, Inc. announced the completion of its merger with Aurinia Pharma U.S., Inc., resulting in the cancellation of certain stock options and the issuance of cash and contingent value rights.

Kezar Life Sciences reports changes in beneficial ownership for Director Graham K. Cooper following the company's merger completion on May 11, 2026.

Kezar Life Sciences has filed a definitive proxy statement with the SEC related to its upcoming shareholder meeting.

Kezar Life Sciences invites stockholders to its 2025 Annual Meeting on June 17, 2025, to vote on director elections, executive compensation, and auditor ratification.

Kezar Life Sciences is holding its annual meeting on June 18, 2024, and is seeking stockholder votes on director elections, executive compensation, auditor ratification, and a potential reverse stock split.

Kezar Life Sciences is asking stockholders to approve a reverse stock split to maintain its Nasdaq listing, alongside other routine proposals at the upcoming annual meeting.

Kezar Life Sciences announced the completion of its merger with Aurinia Pharma U.S., Inc., resulting in the cancellation of all outstanding common stock, with Tang Capital entities reporting no beneficial ownership post-merger.

Tang Capital Management and related entities have agreed to tender their 9.0% stake in Kezar Life Sciences in support of the merger with Aurinia Pharmaceuticals, rescinding a prior acquisition proposal.

Equal Talent Investments Limited, a significant shareholder in Kezar Life Sciences, Inc., has filed an amended Schedule 13D to report a change in its sole director, with Tracy Gia Yunn Tsoi replacing Suk Ying Pauli Ng.

Morningside Venture Investments Limited and Equal Talent Investments Limited have significantly reduced their beneficial ownership in Kezar Life Sciences, Inc. through recent stock sales.

Baselake Partners, LP, Baselake Management, LLC, and David Paolella have filed an amendment to their Schedule 13G, reporting a 0% beneficial ownership stake in Kezar Life Sciences, Inc.

Baselake Partners, LP, Baselake Management, LLC, and David Paolella have filed an amendment to their Schedule 13G, reporting a 0% beneficial ownership stake in Kezar Life Sciences, Inc.

BML Investment Partners, L.P. has filed a Schedule 13G amendment indicating no beneficial ownership of Kezar Life Sciences, Inc. common stock as of May 11, 2026.

Baselake Partners, LP, along with its management entity and managing member, has reported a 5.3% beneficial ownership stake in Kezar Life Sciences, Inc.

Stonepine Capital Management and related entities have reported a 2.1% passive beneficial ownership stake in Kezar Life Sciences, Inc. as of December 31, 2025.

BML Investment Partners, L.P. has reported a 9.8% beneficial ownership stake in Kezar Life Sciences, Inc., holding 720,787 shares of common stock.